Division of Pulmonology and Allergy, Department of Internal Medicine, College of Medicine, Yeungnam University and Regional Center for Respiratory Diseases, Yeungnam University Medical Center, Daegu, Korea.
Aging Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea.
Yonsei Med J. 2020 May;61(5):431-437. doi: 10.3349/ymj.2020.61.5.431.
Although some information on the epidemiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and a few selected cases has been reported, data on the clinical characteristics and outcomes of patients hospitalized therewith in South Korea are lacking. We conducted a retrospective single-center study of 98 consecutive hospitalized patients with confirmed SARS-CoV-2 infection at Yeungnam University Medical Center in Daegu, South Korea. Sixty patients were women (61.2%), and the mean age was 55.4±17.1 years. Thirteen patients (13.3%) were treated in the intensive care unit (ICU). The mean interval from symptom onset to hospitalization was 7.7±4.5 days. Patients who received ICU care were significantly older and were more likely to have diabetes mellitus. The National Early Warning Score on the day of admission was significantly higher in patients requiring ICU care. Acute respiratory distress syndrome (13/13 patients; 100%), septic shock (9/13; 69.2%), acute cardiac injury (9/13; 69.2%), and acute kidney injury (8/13; 61.5%) were more common in patients who received ICU care. All patients received antibiotic therapy, and most (97/98 patients; 99.0%) received antiviral therapy (lopinavir/ritonavir). Hydroxychloroquine was used in 79 patients (80.6%), and glucocorticoid therapy was used in 18 patients (18.4%). In complete blood counts, lymphopenia was the most common finding (40/98 patients; 40.8%). Levels of all proinflammatory cytokines were significantly higher in ICU patients. As of March 29, 2020, the mortality rate was 5.1%. Here, we report the clinical characteristics and laboratory findings of SARS-CoV-2 patients in South Korea up to March 29, 2020.
虽然已经报道了一些关于严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的流行病学信息和一些精选病例,但缺乏关于韩国住院患者的临床特征和结局的数据。我们对韩国大邱庆北大学医院收治的 98 例确诊 SARS-CoV-2 感染住院患者进行了回顾性单中心研究。60 例患者为女性(61.2%),平均年龄为 55.4±17.1 岁。13 例(13.3%)患者在重症监护病房(ICU)接受治疗。从症状出现到住院的平均时间为 7.7±4.5 天。需要 ICU 护理的患者年龄明显较大,且更有可能患有糖尿病。需要 ICU 护理的患者入院当天的国家早期预警评分明显较高。在接受 ICU 护理的患者中,急性呼吸窘迫综合征(13/13 例;100%)、感染性休克(9/13 例;69.2%)、急性心脏损伤(9/13 例;69.2%)和急性肾损伤(8/13 例;61.5%)更为常见。所有患者均接受抗生素治疗,大多数(98 例患者中的 97 例;99.0%)接受抗病毒治疗(洛匹那韦/利托那韦)。79 例患者(80.6%)使用羟氯喹,18 例患者(18.4%)使用糖皮质激素治疗。在全血细胞计数中,最常见的发现是淋巴细胞减少(40/98 例;40.8%)。所有促炎细胞因子的水平在 ICU 患者中均显著升高。截至 2020 年 3 月 29 日,死亡率为 5.1%。在这里,我们报告了截至 2020 年 3 月 29 日韩国 SARS-CoV-2 患者的临床特征和实验室检查结果。